Immunotherapy plus low-dose Avastin for recurrent oligodendroglioma
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial tests an immune treatment (sintilimab, an anti–PD-1 antibody) together with low-dose bevacizumab (Avastin) to treat oligodendroglioma that has come back, including cases detected by tumor DNA in body fluid. It aims to slow or control tumor growth and help reduce symptoms by targeting both the tumor and its blood supply.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of oligodendroglioma, WHO grade 3
- You had surgery at this study center with a special reservoir placed for easy collection of tumor fluid after surgery
- Your surgery must be more than 28 days ago, and you must be fully recovered without safety issues
- You must be able to do frequent study visits, MRI scans, and tumor fluid (TISF) collections
- You must be well enough to participate (Karnofsky score 70+), and expected to live more than 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—sintilimab (an immunotherapy that helps your immune system fight cancer) and low-dose bevacizumab (a drug that blocks blood vessel growth to tumors)—for people with astrocytoma that has come back. The goal is to see if this combination can slow or stop the tumor's growth.
This trial tests a combination of two drugs—sintilimab (an immunotherapy that helps your immune system fight cancer) and low-dose bevacizumab (which blocks blood vessel growth to tumors)—for people whose glioblastoma has returned after standard treatment. The goal is to see if this combo can slow or stop the cancer with fewer side effects.
This study tests a combination of two drugs for people with glioblastoma that has come back after treatment with bevacizumab (a drug that targets blood vessel growth). The goal is to see if this new combination can shrink the tumor or slow its growth.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
This trial tests a personalized immune cell therapy for adults with a specific type of brain tumor (oligodendroglioma) that has come back. The treatment uses your own immune cells to target the tumor.
This study tests whether adding focused ultrasound to the standard drug Avastin (bevacizumab) can help treat recurrent glioblastoma. The ultrasound may help more of the drug reach the tumor.
Hear when a new Oligodendroglioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.